Spots Global Cancer Trial Database for hepatic arterial infusion chemotherapy
Every month we try and update this database with for hepatic arterial infusion chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | NCT04627363 | Hepatocellular ... Bevacizumab Liver Neoplasms Toripalimab Oxaliplatin | Hepatic arteria... Bevacizumab Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma | NCT06184841 | Hepatic Arteria... Liver Metastase... Esophageal Squa... | HAIC combined w... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | NCT04618367 | Carcinoma, Hepa... Liver Neoplasms Sintilimab Portal Vein Tum... | Hepatic arteria... Lenvatinib Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | NCT06333561 | Hepatocellular ... Lenvatinib PD-1 Inhibitor Hepatic Arteria... | Hepatic arteria... Lenvatinib Tislelizumab Toripalimab Sintilimab Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma | NCT05416073 | Hepatocellular ... Transarterial C... Hepatic Arteria... Pain | Esketamine Sufentanil | 18 Years - 80 Years | The Second Affiliated Hospital of Chongqing Medical University | |
| A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC | NCT01997957 | Hepatocellular ... | S-1 | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma | NCT05489692 | Intrahepatic Ch... | hepatic arteria... | 18 Years - | Sun Yat-sen University | |
| HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | NCT05348811 | Cholangiocarcin... | HAIC combined w... | 18 Years - 75 Years | Zhongda Hospital | |
| HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | NCT05886465 | Hepatocellular ... | Atezolizumab Bevacizumab HAIC with FOLFO... | 18 Years - 75 Years | Sun Yat-sen University | |
| Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC | NCT05533892 | Hepatocellular ... | Nocardia rubra ... Hepatic arteria... Lenvatinib Tislelizumab | 18 Years - | Tongji Hospital | |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC | NCT04597970 | Transarterial C... Hepatocellular ... | cTACE-HAIC | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil | NCT02987699 | HepatoCellular ... | 5-Fu, oxaliplat... 5-Fu, oxaliplat... 5-Fu, oxaliplat... | 18 Years - 75 Years | Sun Yat-sen University | |
| Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation | NCT05833126 | Recurrent Liver... | Hepatic arteria... | 18 Years - 75 Years | Third Affiliated Hospital, Sun Yat-Sen University | |
| HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) | NCT06210334 | Hepatocellular ... | Tislelizumab Lenvatinib | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT06187961 | Hepatocellular ... | HAIC Lenvatinib plus... | 18 Years - 75 Years | Tongji Hospital | |
| Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | NCT06001567 | Thrombocytopeni... Hepatocellular ... | Avatrombopag | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University | |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | NCT05862181 | Advanced Hepato... | DEB-TACE plus H... | 18 Years - | Peking University Cancer Hospital & Institute | |
| HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | NCT03812783 | Hepatocellular ... | Hepatic arteria... Folfox Protocol Sorafenib Hepatic arteria... FOLFIRINOX | 18 Years - 75 Years | Sun Yat-sen University | |
| Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma | NCT05573282 | Hepatocellular ... | Regorafenib com... | 18 Years - 75 Years | Sun Yat-sen University | |
| The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study | NCT05121571 | Hepatocellular ... | HAIC Sorafenib | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Plus Lenvatinib and Toripalimab for Advanced HCC | NCT04044313 | Hepatocellular ... | Hepatic arteria... Lenvatinib Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC | NCT04597970 | Transarterial C... Hepatocellular ... | cTACE-HAIC | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT05313282 | C-staged Hepato... | Hepatic Arteria... Apatinib combin... | 18 Years - | Sun Yat-sen University | |
| HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC | NCT03775395 | Hepatocellular ... | Lenvatinib Sorafenib Hepatic arteria... | 18 Years - 75 Years | Sun Yat-sen University | |
| Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma | NCT01088581 | Hepatocellular ... | Adjuvant group | 18 Years - 70 Years | Yonsei University | |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | NCT04962958 | Carcinoma Carcinoma, Hepa... Liver Neoplasms Digestive Syste... Antineoplastic ... Donafenib Fluorouracil Oxaliplatin Antimetabolites | Hepatic arteria... Folfox Protocol Donafenib | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC | NCT05532319 | Liver Cancer | HAIC sequential... | 18 Years - 70 Years | Guangxi Medical University | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis | NCT03009461 | HepatoCellular ... Portal Vein Thr... | HAIC Sorafenib | 18 Years - 75 Years | Peking University | |
| Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC | NCT05533892 | Hepatocellular ... | Nocardia rubra ... Hepatic arteria... Lenvatinib Tislelizumab | 18 Years - | Tongji Hospital | |
| Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | NCT05003700 | Hepatocellular ... | Hepatic arteria... Lenvatinib Camrelizumab | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection | NCT02767375 | Hepatocellular ... | Oxaliplatin(OXA... Hepatic arteria... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection | NCT02767375 | Hepatocellular ... | Oxaliplatin(OXA... Hepatic arteria... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | NCT03722498 | Hepatocellular ... | HAIC of FOLFOX Sorafenib | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC | NCT03869034 | Hepatocellular ... | HAIC+PD1 HAIC | 18 Years - 70 Years | Sun Yat-sen University | |
| Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma | NCT01088581 | Hepatocellular ... | Adjuvant group | 18 Years - 70 Years | Yonsei University | |
| HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC | NCT04217954 | Advanced Biliar... | OXA, 5-FU and b... | 18 Years - 80 Years | Peking University | |
| HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | NCT03780634 | Hepatocellular ... | HAIC PD-1 antibody Sorafenib | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | NCT06333561 | Hepatocellular ... Lenvatinib PD-1 Inhibitor Hepatic Arteria... | Hepatic arteria... Lenvatinib Tislelizumab Toripalimab Sintilimab Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | NCT05400902 | Intrahepatic Ch... | HAIC Combined w... | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | NCT05348811 | Cholangiocarcin... | HAIC combined w... | 18 Years - 75 Years | Zhongda Hospital | |
| HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC | NCT03775395 | Hepatocellular ... | Lenvatinib Sorafenib Hepatic arteria... | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | NCT04135690 | Hepatocellular ... | Hepatic arteria... Toripalimab Sorafenib systemic treatm... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma | NCT02981498 | Hepatocellular ... | Hepatic arteria... Folfox Protocol | 18 Years - 75 Years | Sun Yat-sen University | |
| FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | NCT06201065 | Hepatocellular ... | Hepatic arteria... Lenvatinib Toripalimab oxaliplatin , f... | 18 Years - 75 Years | Sun Yat-sen University | |
| Biliary Drainage Plus HAIC in Locally Advanced pCCA | NCT05024513 | Perihilar Chola... | oxaliplatin and... Biliary Drainag... Best Supportive... External biliar... | 18 Years - 80 Years | Peking University | |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | NCT04627363 | Hepatocellular ... Bevacizumab Liver Neoplasms Toripalimab Oxaliplatin | Hepatic arteria... Bevacizumab Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | NCT02856126 | Hepatocellular ... | Hepatic arteria... Transarterial c... TACE regimen HAIC Regimen Oral Sorafenib | 18 Years - 75 Years | Sun Yat-sen University | |
| Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | NCT05406206 | Advanced Colore... Liver Metastasi... | Fruquintinib Hepatic Arteria... | 18 Years - | Peking University Cancer Hospital & Institute | |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | NCT05862181 | Advanced Hepato... | DEB-TACE plus H... | 18 Years - | Peking University Cancer Hospital & Institute | |
| A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents | NCT05718492 | Hepatocellular ... | digital subtrac... FOLFOX (oxalipl... | 18 Years - 75 Years | Sun Yat-sen University | |
| Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | NCT06001567 | Thrombocytopeni... Hepatocellular ... | Avatrombopag | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University | |
| HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | NCT06389500 | Biliary Tract C... | Adebrelimab Lenvatinib Hepatic Arteria... | 18 Years - 75 Years | Harbin Medical University | |
| HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | NCT05866172 | Hepatocellular ... | HAIC Zoledronic acid | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma | NCT05489692 | Intrahepatic Ch... | hepatic arteria... | 18 Years - | Sun Yat-sen University | |
| Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT | NCT06265883 | Hepatocellular ... | Len+DEB-TACE+HA... Len+DEB-TACE | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| DEB-TACE+HAIC vs. HAIC for Large HCC | NCT05263219 | Unresectable He... | dTACE-HAIC HAIC dTACE-HAIC prot... HAIC protocol | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma | NCT01088581 | Hepatocellular ... | Adjuvant group | 18 Years - 70 Years | Yonsei University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
